Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Study Overview

This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM).

The drug involved in this study is:

-Daratumumab

Study Description

A Phase II Study of the CD38 Antibody Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

  • ClinicalTrials.gov Identifier: NCT03236428
  • Protocol Number: 17-212
  • Principal Investigator: Jacalyn Rosenblatt

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000